Adicet Bio, Inc. is a privately held, pre-clinical stage biotechnology company engaged in the design and development of cutting-edge immunotherapies for cancer and other disease indications, with a focus on novel universal immune cell therapies (uICT).
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/27/16 | $51,000,000 | Series A |
Novartis Venture Funds OrbiMed Advisors Pontifax | undisclosed |
| 10/03/19 | $80,000,000 | Series B |
aMoon2 Fund Consensus Business Group DSC Investment Handok Johnson & Johnson Innovation KB Investment Co Novartis Venture Funds OCI Enterprises OrbiMed Advisors Regeneron Pharmaceuticals Samsung Venture Investment SBI JI Innovation Fund | undisclosed |
